Unicycive Therapeutics (UNCY) to Release Quarterly Earnings on Monday

Key Points

• Unicycive Therapeutics will report quarterly results before the market opens on Monday, March 30, with analysts forecasting an expected loss of ($0.46) per share.
• Wall Street sentiment is mixed but tilted positive, with a consensus rating of "Moderate Buy" (four Buys, one Sell) and an average price target of $34.33, versus a current share price around $6.73 and a market cap of roughly $144.6 million.
• The company, which is developing kidney-disease treatments including Renazorb and UNI‑494, has substantial institutional interest (about 40.42% owned by hedge funds and institutions) after recent new stakes from firms such as Millennium Management and Cantor Fitzgerald.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) is projected to release its results before the market opens on Monday, March 30th. Analysts expect Unicycive Therapeutics to post earnings of ($0.46) per share for the quarter.

Unicycive Therapeutics Trading Down 1.2%

Shares of NASDAQ UNCY opened at $6.73 on Monday. The company has a 50 day simple moving average of $6.63 and a two-hundred day simple moving average of $5.66. The stock has a market cap of $144.63 million, a price-to-earnings ratio of -1.70 and a beta of 1.82. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $11.00.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Unicycive Therapeutics in a research report on Monday, December 29th. Guggenheim reaffirmed a "buy" rating on shares of Unicycive Therapeutics in a research report on Tuesday, December 30th. Finally, Westpark Capital initiated coverage on Unicycive Therapeutics in a research note on Thursday, February 19th. They set a "buy" rating for the company. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $34.33.

Hedge Funds Weigh In On Unicycive Therapeutics

Institutional investors have recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new stake in Unicycive Therapeutics during the fourth quarter worth $226,000. Millennium Management LLC purchased a new stake in Unicycive Therapeutics during the fourth quarter worth $5,856,000. Cantor Fitzgerald L. P. acquired a new stake in Unicycive Therapeutics during the fourth quarter valued at $1,154,000. OMERS ADMINISTRATION Corp purchased a new position in Unicycive Therapeutics in the fourth quarter valued at $451,000. Finally, State Street Corp increased its holdings in Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company's stock valued at $376,000 after buying an additional 10,400 shares in the last quarter. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.